MarketCap
Facebook
X
Telegram
Bicycle Therapeutics plc Income Statement 2025-2011 | BCYC
Brief overview of revenue and earnings at Bicycle Therapeutics plc
The figures are compared over a five-year interval. According to figures from Bicycle Therapeutics plc, revenue changed from $10.4 million to $72.6 million over five years. The total change was +598.6%, with a CAGR of approximately 47.5%. Revenue growth reflects a pronounced phase of business expansion.
The five-year EBITDA result moved by −374.8%: from −$50.7 million to −$241 million. Operating performance weakened relative to revenue. At the operating-margin level, the figure shifted from −487.8% to −331.5%. A wider margin confirms stronger operating efficiency.
Comparing the endpoints shows a move from −51 million dollars to −219 million dollars. The loss widened and increased the financial risk.
Over the period, capitalization shifted from $513 million to $351 million (−31.6%). Financial performance is stronger than the share-price trend.
Conclusion
The results contain several connected negative signals. The strongest signals are an improving EBITDA margin and revenue expansion. The main areas of concern are lower net income, a weaker market valuation and limited operating profitability. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Bicycle Therapeutics plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
351 M | 654 M | 802 M | 680 M | 1.22 B | 513 M | 121 M | - | - | - | - | - | - | - | - |
Shares |
69.3 M | 58.2 M | 35.6 M | 29.7 M | 25.1 M | 19.1 M | 11 M | - | - | - | - | - | - | - | - |
Historical Prices |
5.07 | 11.2 | 22.5 | 22.9 | 48.8 | 26.8 | 10.9 | - | - | - | - | - | - | - | - |
Net Income |
-219 M | -169 M | -181 M | -113 M | -66.8 M | -51 M | -30.6 M | -21.8 M | -16.3 M | - | - | - | - | - | - |
Revenue |
72.6 M | 35.3 M | 27 M | 14.5 M | 11.7 M | 10.4 M | 13.8 M | 7.14 M | 2.06 M | - | - | - | - | - | - |
Operating Income |
-247 M | -210 M | -190 M | -117 M | -65.6 M | -52 M | -26.3 M | -21.7 M | -16.2 M | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | 2.98 M | 457 K | -5.38 M | -665 K | -119 K | - | - | - | - | - | - |
EBITDA |
-241 M | -203 M | -183 M | -113 M | -64.2 M | -50.7 M | -25.3 M | -21 M | -15.9 M | - | - | - | - | - | - |
Operating Expenses |
320 M | 245 M | 217 M | 131 M | 77.3 M | 62.4 M | 40.1 M | 28.9 M | 18.3 M | - | - | - | - | - | - |
General and Administrative Expenses |
79.4 M | 72.2 M | 60.4 M | 49.5 M | 32.4 M | 29.2 M | 14.6 M | 8.12 M | 6.41 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Bicycle Therapeutics plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
69.3 M | 69.2 M | 69.1 M | 69 M | 52 M | 42.6 M | 42.4 M | 39.6 M | 30.2 M | 30 M | 29.9 M | 29.7 M | 29.6 M | 29.6 M | 29.6 M | 25 M | 24.1 M | 22.1 M | 21.1 M | 19.4 M | 18.1 M | 18 M | 17.9 M | 17.9 M | 7.3 M | 834 K | 503 K | 434 K | 420 K | 397 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-79 M | -60.8 M | - | -50.8 M | -39.8 M | -26.6 M | - | -49.9 M | -42.6 M | -39.1 M | - | -28.3 M | -26.8 M | -27.6 M | - | -14.7 M | -17.9 M | -16.2 M | -17.4 M | -10.1 M | -12.1 M | -11.3 M | -4.41 M | -9.48 M | -10.2 M | -6.5 M | -6.64 M | -7.69 M | -4.98 M | -2.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
2.92 M | 9.98 M | - | 2.68 M | 9.36 M | 19.5 M | - | 5.35 M | 11.4 M | 4.9 M | - | 3.04 M | 4.38 M | 3.86 M | - | 4.33 M | 1.78 M | 1.81 M | 3.85 M | 3.84 M | 1.57 M | 1.13 M | 5.28 M | 614 K | 1.52 M | 6.38 M | 1.06 M | 1.61 M | 1.66 M | 2.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-86.6 M | -70.2 M | - | -63.8 M | -46.6 M | -31.7 M | - | -50.8 M | -43.1 M | -41.8 M | - | -29.8 M | -27.3 M | -27.4 M | - | -14.3 M | -17.3 M | -16 M | - | -10.7 M | -12.6 M | -11.6 M | - | -10.3 M | -7.99 M | -3.29 M | - | -6.36 M | -4.96 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | 821 K | - | 814 K | 821 K | 808 K | - | 817 K | 883 K | 818 K | - | 823 K | 819 K | 522 K | - | - | - | - | - | -5.38 M | -2.18 M | -3.19 M | - | -1.36 M | -73 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-84.9 M | -68.6 M | - | -61.6 M | -45 M | -30.1 M | - | -49.1 M | -41.5 M | -40.2 M | - | -28.5 M | -26.7 M | -27 M | - | -13.3 M | -17 M | -15.7 M | - | -9.73 M | -12 M | -11.3 M | - | -9.57 M | -7.54 M | -3.08 M | - | -5.83 M | -4.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
89.5 M | 80.2 M | - | 66.5 M | 56 M | 51.2 M | - | 56.1 M | 54.5 M | 46.7 M | - | 32.8 M | 31.7 M | 31.2 M | - | 18.6 M | 19.1 M | 17.8 M | 20.9 M | 14.5 M | 14.2 M | 12.8 M | 10 M | 10.9 M | 9.51 M | 9.68 M | 8.6 M | 7.97 M | 6.62 M | 5.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
18.5 M | 21.1 M | - | 18.3 M | 15.9 M | 16.4 M | - | 16.3 M | 14.8 M | 14.5 M | - | 10 M | 11.8 M | 17 M | - | 8.11 M | 7.34 M | 8.14 M | - | 7.15 M | 6.2 M | 5 M | - | 4.79 M | 2.97 M | 3.4 M | - | 2.32 M | 1.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Bicycle Therapeutics plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
